Oncocyte Corp
For the period ended Jun 30, 2024. Filed Aug 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 8, 2024
IMDX$2.50+0.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except per share data)
| June 30, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| (Unaudited) | ||
| ASSETS | ||
| CURRENT ASSETS | ||
| Cash and cash equivalents | $9,256 | $9,432 |
| Accounts receivable, net of allowance for credit losses of $1 and $5, respectively | 85 | 484 |
| Prepaid expenses and other current assets | 595 | 643 |
| Assets held for sale | 32 | 139 |
| Total current assets | 9,968 | 10,698 |
| NONCURRENT ASSETS | ||
| Right-of-use and financing lease assets, net | 2,591 | 1,637 |
| Machinery and equipment, net, and construction in progress | 3,347 | 3,799 |
| Intangible assets, net | 56,551 | 56,595 |
| Restricted cash | 1,700 | 1,700 |
| Other noncurrent assets | 563 | 463 |
| TOTAL ASSETS | $74,720 | $74,892 |
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||
| CURRENT LIABILITIES | ||
| Accounts payable | $1,051 | $953 |
| Accrued compensation | 1,309 | 1,649 |
| Accrued royalties | 1,116 | 1,116 |
| Accrued expenses and other current liabilities | 379 | 452 |
| Accrued severance from acquisition | 2,314 | 2,314 |
| Right-of-use and financing lease liabilities, current | 1,029 | 665 |
| Current liabilities of discontinued operations (Note 11) | - | 45 |
| Total current liabilities | 7,198 | 7,194 |
| NONCURRENT LIABILITIES | ||
| Right-of-use and financing lease liabilities, noncurrent | 2,638 | 2,204 |
| Contingent consideration liabilities | 42,181 | 39,900 |
| TOTAL LIABILITIES | 52,017 | 49,298 |
| Commitments and contingencies (Note 6) | ||
| Series A Redeemable Convertible Preferred Stock, no par value; stated value $1,000 per share; 5 shares issued and outstanding at December 31, 2023; aggregate liquidation preference of $5,296 as of December 31, 2023 | - | 5,126 |
| SHAREHOLDERS’ EQUITY | ||
| Preferred stock, no par value, 5,000 shares authorized; no shares issued and outstanding | - | - |
| Common stock, no par value, 230,000 shares authorized; 13,368 and 8,261 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively | 326,201 | 310,295 |
| Accumulated other comprehensive income | 37 | 49 |
| Accumulated deficit | (303,535) | (289,876) |
| Total shareholders’ equity | 22,703 | 20,468 |
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $74,720 | $74,892 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.